September 13, 2024 07:00 AM EDTUpdated 08:00 AM
Peer Review

Doug Williams re­turns with a ‘FIT’ bet on CAR-Ts; Bio­gen ap­points Mene Pan­ga­los to board

Alex Hoffman

Senior Editor

Kathy Wong

Editor

Kyle LaHucik

Senior Reporter

In­dus­try vet­er­an Doug Williams is back with a new ap­proach to CAR-T cell ther­a­pies that he ex­pects to take in­to the clin­ic in the US …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

All of 23and­Me's in­de­pen­dent board mem­bers re­sign over dis­agree­ments with CEO

Bad trip: How cul­ture con­flict and a need for cash near­ly broke Lykos

Cigna sues FTC, call­ing for with­draw­al of 'bi­ased, er­ro­neous' PBM re­port

No­var­tis’ Kisqali snags FDA ap­proval to re­duce re­cur­rence in pa­tients with ear­ly forms of breast can­cer

Af­ter land­ing a key win in a com­mon can­cer con­di­tion, Pfiz­er faces a big test in Phase 3

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times